President, Head of Research and Development and Former Chief Executive Officer · Syndax Pharmaceuticals Inc (SNDX)

Briggs Morrison

A named executive officer of Syndax Pharmaceuticals in every fiscal year CompBrief holds from FY2017 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$2,374,171

Salary $637,500Stock awards $0

FY2021: $3,904,316

5th of 7 named executive officers at Syndax Pharmaceuticals by FY2022 total.

7 named officers on file for Syndax Pharmaceuticals, FY2022

Briggs Morrison’s pay file — $29

  • 6 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • SNDX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Syndax Pharmaceuticals’s whole pay program stands against its peers

  • Syndax Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SNDX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 7, 2023 (DEF 14A).

Free

Get Briggs Morrison’s full pay file as a PDF — free

More than this page: up to 10 years of Briggs’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Briggs Morrison compensation by year

Syndax Pharmaceuticals Summary Compensation Table · all 6 fiscal years held
In US dollars, as Syndax Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021FY2022
Salary$549,585$566,073$583,055$600,547$618,563$637,500
Bonus$0$0$0$0$0$0
Stock awards$0$0$0$0$0$0
Option awards$920,012$1,263,780$763,574$1,273,590$2,968,473$1,393,983
Non-equity incentive$204,500$247,660$262,375$285,260$309,280$334,688
Pension and deferred compensation$0$0$0$0$0$0
All other$3,000$3,000$3,000$6,000$8,000$8,000
Total$1,677,097$2,080,513$1,612,004$2,165,397$3,904,316$2,374,171

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Syndax Pharmaceuticals Inc DEF 14A filed April 7, 2023, accession 0000950170-23-012189, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Syndax Pharmaceuticals Inc filed document, accession 0000950170-23-012189. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2023.

$1.7M
$2.1M
$1.6M
$2.2M
$3.9M
$2.4M
FY17
FY18
FY19
FY20
FY21
FY22
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option60,000—$15.79
Option77,083—$15.79
Option101,563—$21.36
Option3,687—$6.38
Option52,542—$9.47

Per the Outstanding Equity Awards at Fiscal Year-End table in Syndax Pharmaceuticals Inc's FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Syndax Pharmaceuticals’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Michael MetzgerChief Executive Officer$4,113,476
Steve SabusChief Commercial Officer$3,916,050
Keith GoldanChief Financial Officer$2,992,538
Catherine MadiganChief Medical Officer$2,643,914
Briggs Morrison · this pagePresident, Head of Research and Development and Former Chief Executive Officer$2,374,171
Luke AlbrechtGeneral Counsel and Secretary$1,468,073
Alexander NolteVice President, Chief Accounting Officer and Former Interim Principal Financial Officer$760,864

Board service

Syndax Pharmaceuticals board · FY2022–FY2023
Director compensation in US dollars, as Syndax Pharmaceuticals reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2023$30,912$0——$30,912
FY2022—————

Each year as the company reported it in Syndax Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Syndax Pharmaceuticals pays directors a $50,000 cash retainer and $366,250 in equity. As stated in Syndax Pharmaceuticals's FY2025 proxy.

The full Syndax Pharmaceuticals compensation record

free company brief

This page is one person within Syndax Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Syndax Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Syndax Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Briggs Morrison's compensation dossier · One-time report. No refunds.